Abstract
IL-23, a clinically novel cytokine, targets CD4+ T cells. Recent IL-1Ra-/- mouse studies have demonstrated that IL-23 indirectly stimulates the differentiation of osteoclast precursors by enhancing IL-17 release from CD4+ T cells. IL-17, in turn, stimulates osteoclastogenesis in osteoclast precursor cells. In this study, we found that IL-23 up-regulates receptor activator of NF-κB ligand expression by CD4+ T cells, and thus contributes to osteoclastogenesis. This indirect pathway is mediated by NF-κB and STAT3. We have also demonstrated that IL-23 can influence osteoclastogenesis positively under the special conditions in the IL-1-dominant milieu of IL-1Ra-/- mice. We propose that IL-23-enhanced osteoclastogenesis is mediated mainly by CD4+ T cells. The results of this study show that IL-23 is a promising therapeutic target for the treatment of arthritis-associated bone destruction.
Original language | English (US) |
---|---|
Pages (from-to) | 1507-1518 |
Number of pages | 12 |
Journal | Journal of Immunology |
Volume | 181 |
Issue number | 2 |
DOIs | |
State | Published - Jul 15 2008 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology